Results 21 to 30 of about 39,162 (280)

Breast cancer characteristics and surgery among women with Li‐Fraumeni syndrome in Germany—A retrospective cohort study

Cancer Medicine, 2021
Background Women with Li‐Fraumeni syndrome (LFS) have elevated breast cancer (BC) risk. Optimal BC treatment strategies in this population are yet unknown.
Nathalie Rippinger, Christine Fischer, Hans‐Peter Sinn, Nicola Dikow, Christian Sutter, Kerstin Rhiem, Sabine Grill, Friedrich W. Cremer, Huu P. Nguyen, Nina Ditsch, Karin Kast, Simone Hettmer, Christian P. Kratz, Sarah Schott   +13 more
doaj   +1 more source

Hereditary Breast and Ovarian Cancer

The Meducator, 2018
Genetic testing for breast cancer 1 (BRCA1) and breast cancer 2 (BRCA2) mutations in clinical oncology is becoming more widely employed around the world.
D. Bobrowski, D. Hu
semanticscholar   +1 more source

Feasibility of structured endurance training and Mediterranean diet in BRCA1 and BRCA2 mutation carriers – an interventional randomized controlled multicenter trial (LIBRE-1)

BMC Cancer, 2017
Background Women with pathogenic BRCA germline mutations have an increased risk for breast and ovarian cancer that seems to be modified by life-style factors.
Marion Kiechle, Ricarda Dukatz, Maryam Yahiaoui-Doktor, Anika Berling, Maryam Basrai, Vera Staiger, Uwe Niederberger, Nicole Marter, Jacqueline Lammert, Sabine Grill, Katharina Pfeifer, Kerstin Rhiem, Rita K. Schmutzler, Matthias Laudes, Michael Siniatchkin, Martin Halle, Stephan C. Bischoff, Christoph Engel   +17 more
doaj   +1 more source

Ask Rosa - The making of a digital genetic conversation tool, a chatbot, about hereditary breast and ovarian cancer.

Patient Education and Counseling, 2021
OBJECTIVE We aimed at developing a pilot version of an app (Rosa) that can perform digital conversations with breast or ovarian cancer patients about genetic BRCA testing, using chatbot technology, to identify best practices for future patient-focused ...
E. Siglen, H. Vetti, Aslaug Beathe Forberg Lunde, Thomas Akselberg Hatlebrekke, N. Strømsvik, Anniken Hamang, Sigrid Tronsli Hovland, Jill Walker Rettberg, V. Steen, Cathrine Bjorvatn   +9 more
semanticscholar   +1 more source

Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history

BMC Cancer, 2018
Background There is no international consensus up to which age women with a diagnosis of triple-negative breast cancer (TNBC) and no family history of breast or ovarian cancer should be offered genetic testing for germline BRCA1 and BRCA2 (gBRCA ...
Christoph Engel, Kerstin Rhiem, Eric Hahnen, Sibylle Loibl, Karsten E. Weber, Sabine Seiler, Silke Zachariae, Jan Hauke, Barbara Wappenschmidt, Anke Waha, Britta Blümcke, Marion Kiechle, Alfons Meindl, Dieter Niederacher, Claus R. Bartram, Dorothee Speiser, Brigitte Schlegelberger, Norbert Arnold, Peter Wieacker, Elena Leinert, Andrea Gehrig, Susanne Briest, Karin Kast, Olaf Riess, Günter Emons, Bernhard H. F. Weber, Jutta Engel, Rita K. Schmutzler, on behalf of the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC)   +28 more
doaj   +1 more source

Knowledge and Anxiety Related to Hereditary Ovarian Cancer in Serous Ovarian Cancer Patients [PDF]

Korean Journal of Women Health Nursing, 2019
PURPOSE: The awareness of hereditary breast and ovarian cancer (HBOC) and BRCA testing is increasing in Korea. Compared to the sizable research on HBOC knowledge among breast cancer women, studies in the ovarian cancer population are limited.
Sang Hee Lee, Hyangkyu Lee, Myong Cheol Lim, Sue Kim   +3 more
doaj   +1 more source

A novel germline BRCA1 mutation identified in a family with hereditary breast and ovarian cancer syndrome

Clinical Medicine Insights: Oncology, 2021
Pathogenic germline mutations occurring in the BRCA1 (MIM:113705 ) and BRCA2 (MIM: 600185) , which always result in truncated protein or nonsense-mediated mRNA decay, have been identified to increase the risk of hereditary breast, ovarian, pancreatic ...
Yanmei Wu, Xiaodong Pan, Juan Dou, Quan Zhang, Yuantong Li, Yuan Sheng, Xishui Liu   +6 more
doaj   +1 more source

Risk assessment and genetic counseling for hereditary breast and ovarian cancer syndromes—Practice resource of the National Society of Genetic Counselors

Journal of Genetic Counseling, 2021
Cancer risk assessment and genetic counseling for hereditary breast and ovarian cancer (HBOC) are a communication process to inform and prepare patients for genetic test results and the related medical management.
J. Berliner, S. Cummings, Brittany Boldt Burnett, C. Ricker   +3 more
semanticscholar   +1 more source

Analysis of RAD51D in ovarian cancer patients and families with a history of ovarian or breast cancer. [PDF]

PLoS ONE, 2013
Mutations in RAD51D have been associated with an increased risk of hereditary ovarian cancer and although they have been observed in the context of breast and ovarian cancer families, the association with breast cancer is unclear. The aim of this current
Ella R Thompson, Simone M Rowley, Sarah Sawyer, kConfab, Diana M Eccles, Alison H Trainer, Gillian Mitchell, Paul A James, Ian G Campbell   +8 more
doaj   +1 more source

Increased Co-Occurrence of Pathogenic Variants in Hereditary Breast and Ovarian Cancer and Lynch Syndromes: A Consequence of Multigene Panel Genetic Testing?

International Journal of Molecular Sciences, 2022
The probability of carrying two pathogenic variants (PVs) in dominant cancer-predisposing genes for hereditary breast and ovarian cancer and lynch syndromes in the same patient is uncommon, except in populations where founder effects exist.
M. Infante, M. Arranz-Ledo, E. Lastra, L. Abella, Raquel Ferreira, Marta Orozco, L. Hernández, N. Martínez, M. Durán   +8 more
semanticscholar   +1 more source